Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Quantum Biopharma Ltd.
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
May 4, 2026
Quantum Biopharma Provides Corporate Update
May 4, 2026
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
May 4, 2026
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
May 4, 2026
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
May 3, 2026
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
May 3, 2026
Quantum BioPharma Provides Corporate Update
May 1, 2026
Quantum BioPharma Provides Corporate Update
May 1, 2026
←
Previous Page
1
2